drugset / Trial / NCT00525616

Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid

NCT00525616 ↗

Phase 3 Completed 18 enrolled University Hospital, Rouen
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The aim of the study is to assess that it will be possible to control with a single cycle of rituximab patient with bullous pemphigoid.

Timeline

Start
2008-12
Primary completion
2013-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Rituximab Monoclonal antibody 1000 mg Intravenous

Indications